Results 161 to 170 of about 54,036 (213)
Some of the next articles are maybe not open access.

Vasopressors in Sepsis

Surgical Infections, 2018
Sepsis accounts for 10% of intensive care unit admissions and significant healthcare costs. Although the mortality rate from sepsis has been decreasing with better critical care, early identification of septic patients, and prompt interventions, the mortality rate remains 20%-30%.Review of the English-language literature.Norepinephrine is the first ...
Kristin P. Colling   +2 more
openaire   +4 more sources

Vasopressors in Obstetrics

Anesthesiology Clinics, 2008
Hypotension is a common, treatable side effect of neuraxial anesthesia, which has significant side effects for the mother and demonstrable biochemical effects in the fetus. It is clear that a shift in management of hypotension in the obstetric population is in order, but we can only speculate on the benefits for the compromised fetus due to the lack of
Jason Reidy, Joanne Douglas
openaire   +3 more sources

Vasopressors for shock

2004
Besides reversing the underlying cause, the first line treatment for the symptoms of shock is usually the administration of intravenous fluids. If this method is not successful, vasopressors such as dopamine, dobutamine, adrenaline, noradrenaline and vasopressin are recommended.
Gunnar Gamper   +5 more
openaire   +3 more sources

Vasopressors and Inotropes in Sepsis

Emergency Medicine Clinics of North America, 2017
Vasopressor and inotropes are beneficial in shock states. Norepinephrine is considered the first-line vasopressor for patients with sepsis-associated hypotension. Dobutamine is considered the first-line inotrope in sepsis, and should be considered for patients with evidence of myocardial dysfunction or ongoing signs of hypoperfusion.
Leeanne Stratton   +2 more
openaire   +3 more sources

Vasopressors and the Kidney

Blood Purification, 2002
The changes in renal perfusion induced by vasopressors depend on their effects on systemic hemodynamics and renal vascular resistance. Both effects are largely influenced by the patient’s underlying condition such as myocardial contractility and vascular responsiveness.
openaire   +3 more sources

Vasopressors and Inotropes

2018
Vasopressors and inotropes are used in the neurosciences intensive care unit to treat hypotension and to augment blood pressure. Hypotension can be attributed to abnormal cardiac output, abnormal intravascular volume or abnormal systemic vascular resistance.
Eelco F. M. Wijdicks, Sarah L. Clark
openaire   +1 more source

Vasopressor Agents in Shock

The American Journal of Nursing, 1975
Critical hemodynamic changes that are observed with the reduction of blood pressure in shock and the use of vasopressor agents as a temporary measure for maintaining arterial pressure so that irreparable tissue damage can be prevented are considered in this review of the use and efficacy of vasopressor agents in shock.
Lewis C. Mills, John H. Moyer
openaire   +3 more sources

VASOPRESSOR COMPONENTS OF PHEOCHROMOCYTOMAS

Annals of Internal Medicine, 1951
Excerpt The purpose of this report is to present analyses of the pressor amine content of two pheochromocytomas and the metabolism of the hypertensive agents in these and a third tumor.
Virgil D. Wiebelhaus   +4 more
openaire   +3 more sources

Vasopressors for Treating Shock

Postgraduate Medicine, 1974
Shock must be treated by correcting the cause for any treatment of hypotension or shock as such is only an adjunctive measure; but the hemodynamic manifestations also need treatment. Vasopressors are helpful and effective under the right circumstances.
Lewis C. Mills, John H. Moyer
openaire   +3 more sources

Vasopressors During CPR

2013
Epinephrine has been the mainstay of drug therapy during advanced cardiopulmonary resuscitation for many years. The rationale for its administration during cardiac arrest is its vasoconstrictive (α) effect, which could improve both coronary and cerebral perfusion pressure by increasing diastolic arterial pressure.
Sandroni Claudio   +2 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy